ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders,...

MaaT Pharma announced today an €18 million Series B financing round including a microbiome-focused US investor, SymBiosis, LLC, and support from its existing investors...

How a baby is born has a profound impact on their microbiome — the community of microbes that colonize the body. That’s the finding of the largest ever study of the newborn...

LiMM Therapeutics was created to lead development of a new class of therapeutic agents - neuronal reprogrammers of innate lymphocytes. The company is based on pioneering...

Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human...

Upheld patent EP2575835 covers therapeutic compositions of clostridial bacterial species derived from the human microbiome. Decision further solidifies Vedanta’s leading IP...

New collaboration to evaluate the potential of bacterial antigens that mimic tumor antigens and neoantigens ("onco-mimics") to drive immune responses.

Funds will be used to advance Axial’s gut-targeted programs in Parkinson’s Disease and Autism Spectrum Disorder. Seventure Partners commits new funding from...